Does the media favor ADCT or PRME?

In the previous week, ADC Therapeutics had 1 more articles in the media than Prime Medicine. MarketBeat recorded 3 mentions for ADC Therapeutics and 2 mentions for Prime Medicine. ADC Therapeutics' average media sentiment score of 0.37 beat Prime Medicine's score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ALT or ADCT?

In the previous week, Altimmune and Altimmune both had 3 articles in the media. ADC Therapeutics' average media sentiment score of 0.37 beat Altimmune's score of 0.36 indicating that ADC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, VALN or ADCT?

Valneva has higher revenue and earnings than ADC Therapeutics. Valneva is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valneva $197.56M 2.59 -$130.33M -$1.87 N/A ADC Therapeutics $79.18M 1.85 -$142.62M -$1.05 N/A

Is VALN or ADCT more profitable?

Valneva has a net margin of -88.87% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -88.87% -107.63% -33.02% ADC Therapeutics -173.02% N/A -44.70%

Is ADCT or PROK more profitable?

ADC Therapeutics has a net margin of -173.02% compared to ProKidney's net margin of -8,131.50%. Company Net Margins Return on Equity Return on Assets ADC Therapeutics -173.02% N/A -44.70% ProKidney -8,131.50% N/A -21.39%

Does the media favor ADCT or CTMX?

In the previous week, ADC Therapeutics had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 3 mentions for ADC Therapeutics and 2 mentions for CytomX Therapeutics. ADC Therapeutics' average media sentiment score of 0.37 beat CytomX Therapeutics' score of -0.33 indicating that ADC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ADC Therapeutics (ADCT) Competitors

$1.15 +0.06 (+5.50%)

Closing price 03:58 PM Eastern

Extended Trading

$1.12 -0.02 (-2.17%)

As of 07:43 PM Eastern

Compare

ADCT vs. PRME, ALT, VALN, PROK, and CTMX

Should you buy ADC Therapeutics stock or one of its competitors? MarketBeat compares ADC Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ADC Therapeutics include Prime Medicine (PRME), Altimmune (ALT), Valneva (VALN), ProKidney (PROK), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry.

How does ADC Therapeutics compare to Prime Medicine?

ADC Therapeutics (NYSE:ADCT) and Prime Medicine (NASDAQ:PRME) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

ADC Therapeutics has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market.

ADC Therapeutics has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$79.18M	1.85	-$142.62M	-$1.05	N/A
Prime Medicine	$4.63M	126.39	-$201.14M	-$1.23	N/A

ADC Therapeutics currently has a consensus price target of $6.25, suggesting a potential upside of 443.48%. Prime Medicine has a consensus price target of $7.38, suggesting a potential upside of 127.62%. Given ADC Therapeutics' higher probable upside, equities analysts clearly believe ADC Therapeutics is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 5.4% of ADC Therapeutics shares are owned by insiders. Comparatively, 16.0% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ADC Therapeutics has a net margin of -173.02% compared to Prime Medicine's net margin of -4,917.55%. ADC Therapeutics' return on equity of 0.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

In the previous week, ADC Therapeutics had 1 more articles in the media than Prime Medicine. MarketBeat recorded 3 mentions for ADC Therapeutics and 2 mentions for Prime Medicine. ADC Therapeutics' average media sentiment score of 0.37 beat Prime Medicine's score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ADC Therapeutics beats Prime Medicine on 10 of the 17 factors compared between the two stocks.

How does ADC Therapeutics compare to Altimmune?

Altimmune (NASDAQ:ALT) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, Altimmune and Altimmune both had 3 articles in the media. ADC Therapeutics' average media sentiment score of 0.37 beat Altimmune's score of 0.36 indicating that ADC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADC Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.1% of Altimmune shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 1.6% of Altimmune shares are held by company insiders. Comparatively, 5.4% of ADC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ADC Therapeutics has a net margin of -173.02% compared to Altimmune's net margin of -214,860.98%. ADC Therapeutics' return on equity of 0.00% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
ADC Therapeutics	-173.02%	N/A	-44.70%

Altimmune has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Altimmune has higher earnings, but lower revenue than ADC Therapeutics. Altimmune is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	14,147.69	-$88.09M	-$0.93	N/A
ADC Therapeutics	$79.18M	1.85	-$142.62M	-$1.05	N/A

Altimmune presently has a consensus price target of $15.71, indicating a potential upside of 440.01%. ADC Therapeutics has a consensus price target of $6.25, indicating a potential upside of 443.48%. Given ADC Therapeutics' higher probable upside, analysts clearly believe ADC Therapeutics is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

ADC Therapeutics beats Altimmune on 8 of the 15 factors compared between the two stocks.

How does ADC Therapeutics compare to Valneva?

Valneva (NASDAQ:VALN) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Valneva presently has a consensus target price of $11.98, suggesting a potential upside of 121.76%. ADC Therapeutics has a consensus target price of $6.25, suggesting a potential upside of 443.48%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe ADC Therapeutics is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Valneva has a net margin of -88.87% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
ADC Therapeutics	-173.02%	N/A	-44.70%

11.4% of Valneva shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 5.4% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valneva has higher revenue and earnings than ADC Therapeutics. Valneva is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.59	-$130.33M	-$1.87	N/A
ADC Therapeutics	$79.18M	1.85	-$142.62M	-$1.05	N/A

Valneva has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

In the previous week, ADC Therapeutics had 3 more articles in the media than Valneva. MarketBeat recorded 3 mentions for ADC Therapeutics and 0 mentions for Valneva. ADC Therapeutics' average media sentiment score of 0.37 beat Valneva's score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Valneva	Neutral
ADC Therapeutics	Neutral

Summary

ADC Therapeutics beats Valneva on 9 of the 15 factors compared between the two stocks.

How does ADC Therapeutics compare to ProKidney?

ADC Therapeutics (NYSE:ADCT) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

ADC Therapeutics currently has a consensus price target of $6.25, suggesting a potential upside of 443.48%. ProKidney has a consensus price target of $7.40, suggesting a potential upside of 311.11%. Given ADC Therapeutics' higher probable upside, equities analysts clearly believe ADC Therapeutics is more favorable than ProKidney.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

ADC Therapeutics has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market.

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 5.4% of ADC Therapeutics shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ProKidney has lower revenue, but higher earnings than ADC Therapeutics. ProKidney is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$79.18M	1.85	-$142.62M	-$1.05	N/A
ProKidney	$890K	610.91	-$68.99M	-$0.53	N/A

ADC Therapeutics has a net margin of -173.02% compared to ProKidney's net margin of -8,131.50%.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
ProKidney	-8,131.50%	N/A	-21.39%

In the previous week, ADC Therapeutics had 3 more articles in the media than ProKidney. MarketBeat recorded 3 mentions for ADC Therapeutics and 0 mentions for ProKidney. ProKidney's average media sentiment score of 1.42 beat ADC Therapeutics' score of 0.37 indicating that ProKidney is being referred to more favorably in the news media.

Company	Overall Sentiment
ADC Therapeutics	Neutral
ProKidney	Positive

Summary

ProKidney beats ADC Therapeutics on 10 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to CytomX Therapeutics?

ADC Therapeutics (NYSE:ADCT) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

In the previous week, ADC Therapeutics had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 3 mentions for ADC Therapeutics and 2 mentions for CytomX Therapeutics. ADC Therapeutics' average media sentiment score of 0.37 beat CytomX Therapeutics' score of -0.33 indicating that ADC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytomX Therapeutics has a net margin of -166.40% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

ADC Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

CytomX Therapeutics has lower revenue, but higher earnings than ADC Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$79.18M	1.85	-$142.62M	-$1.05	N/A
CytomX Therapeutics	$76.20M	7.04	-$17.37M	-$0.41	N/A

41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 5.4% of ADC Therapeutics shares are owned by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ADC Therapeutics currently has a consensus target price of $6.25, suggesting a potential upside of 443.48%. CytomX Therapeutics has a consensus target price of $12.10, suggesting a potential upside of 284.13%. Given ADC Therapeutics' higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Summary

CytomX Therapeutics beats ADC Therapeutics on 10 of the 17 factors compared between the two stocks.

Get ADC Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADCT vs. The Competition

Export

Metric	ADC Therapeutics	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$138.64M	$3.45B	$6.45B	$23.26B
Dividend Yield	N/A	2.30%	2.69%	4.07%
P/E Ratio	-1.10	19.75	24.92	31.08
Price / Sales	1.85	331.30	528.51	21.86
Price / Cash	N/A	128.56	44.82	24.45
Price / Book	-0.77	8.29	10.79	4.64
Net Income	-$142.62M	$23.85M	$3.56B	$1.07B
7 Day Performance	15.69%	5.21%	1.67%	-1.04%
1 Month Performance	-66.13%	2.19%	0.43%	0.18%
1 Year Performance	-57.09%	60.99%	32.84%	24.25%

ADC Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADCT ADC Therapeutics	2.4471 of 5 stars	$1.15 +5.5%	$6.25 +443.5%	-60.4%	$138.64M	$79.18M	N/A	310	News Coverage
PRME Prime Medicine	1.6261 of 5 stars	$2.83 -2.3%	$7.65 +169.9%	N/A	$510.25M	$4.63M	N/A	N/A	Analyst Forecast
ALT Altimmune	2.0546 of 5 stars	$2.61 -1.3%	$16.67 +539.8%	-58.4%	$506.59M	$40K	N/A	50	Analyst Forecast Options Volume
VALN Valneva	1.5964 of 5 stars	$5.33 -1.1%	$11.98 +124.7%	-5.4%	$505.76M	$197.56M	N/A	700	Positive News
PROK ProKidney	2.4569 of 5 stars	$1.67 -0.3%	$7.40 +344.4%	+175.7%	$502.93M	$890K	N/A	3	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ADCT) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADC Therapeutics (ADCT) Competitors

ADCT vs. PRME, ALT, VALN, PROK, and CTMX

How does ADC Therapeutics compare to Prime Medicine?

Summary

How does ADC Therapeutics compare to Altimmune?

Summary

How does ADC Therapeutics compare to Valneva?

Summary

How does ADC Therapeutics compare to ProKidney?

Summary

How does ADC Therapeutics compare to CytomX Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADC Therapeutics (ADCT) Competitors

ADCT vs. PRME, ALT, VALN, PROK, and CTMX

How does ADC Therapeutics compare to Prime Medicine?

Which has more volatility and risk, ADCT or PRME?

Which has preferable earnings & valuation, ADCT or PRME?

Do analysts rate ADCT or PRME?

Do insiders and institutionals hold more shares of ADCT or PRME?

Is ADCT or PRME more profitable?

Does the media favor ADCT or PRME?

Summary

How does ADC Therapeutics compare to Altimmune?

Does the media refer more to ALT or ADCT?

Do institutionals and insiders have more ownership in ALT or ADCT?

Is ALT or ADCT more profitable?

Which has more risk and volatility, ALT or ADCT?

Which has better valuation and earnings, ALT or ADCT?

Do analysts rate ALT or ADCT?

Summary

How does ADC Therapeutics compare to Valneva?

Do analysts rate VALN or ADCT?

Is VALN or ADCT more profitable?

Do institutionals & insiders have more ownership in VALN or ADCT?

Which has stronger earnings & valuation, VALN or ADCT?

Which has more volatility and risk, VALN or ADCT?

Does the media favor VALN or ADCT?

Summary

How does ADC Therapeutics compare to ProKidney?

Do analysts prefer ADCT or PROK?

Which has more volatility and risk, ADCT or PROK?

Do insiders and institutionals hold more shares of ADCT or PROK?

Which has preferable valuation and earnings, ADCT or PROK?

Is ADCT or PROK more profitable?

Does the media refer more to ADCT or PROK?

Summary

How does ADC Therapeutics compare to CytomX Therapeutics?

Does the media favor ADCT or CTMX?

Is ADCT or CTMX more profitable?

Which has more risk & volatility, ADCT or CTMX?

Which has higher earnings and valuation, ADCT or CTMX?

Do insiders and institutionals have more ownership in ADCT or CTMX?

Do analysts rate ADCT or CTMX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools